Innovating.works Conecta tu I+D

OPTIMA: Optimal treatment for patients with solid tumours in Europe through Artificial intelligence TTOPSTART BV participó en un H2020: H2020-JTI-IMI2-2020-23-two-stage OPTIMA is a multi-stakeholder-led consortium with the vision that each and every patient should have access to the most up-to-date individua...
2021-10-18 - 2026-09-30 | Financiado

INTERVENE: International consortium for integrative genomics prediction TTOPSTART BV participó en un H2020: H2020-SC1-FA-DTS-2018-2020 The aim of INTERVENE is to develop and test next generation tools for disease prevention, diagnosis, and personalised treatment utilizing th...
2020-12-07 - 2025-12-31 | Financiado

BIGPICTURE: Central Repository for Digital Pathology TTOPSTART BV participó en un H2020: H2020-JTI-IMI2-2019-18-two-stage BIGPICTURE, a pathology-led consortium, has the vision to become the catalyst in digital transformation in Pathology. Our mission is to crea...
2020-11-26 - 2027-01-31 | Financiado

AMELIE: Anchored Muscle cELls for IncontinencE TTOPSTART BV participó en un H2020: H2020-SC1-BHC-2018-2020 Faecal incontinence (FI) is a common condition affecting ~67 million people in Europe, seriously impairing living and productivity of affect...
2020-05-06 - 2025-08-31 | Financiado

Immune-Image: Immune Image Specific Imaging of Immune Cell Dynamics Using Novel Tracer Strategies TTOPSTART BV participó en un H2020: H2020-JTI-IMI2-2018-14-two-stage Immunotherapies have emerged as effective treatments for immune system-related diseases, such as cancer and inflammatory diseases. Although...
2019-09-26 - 2026-03-31 | Financiado

ConcePTION: Building an ecosystem for better monitoring and communicating of medication safety in pregnancy and... TTOPSTART BV participó en un H2020: H2020-JTI-IMI2-2017-13-two-stage ConcePTION partners have united around a shared vision that we have a societal obligation to radically and rapidly reduce uncertainty about...
2019-05-06 - 2024-12-31 | Financiado

TICARDIO: Thrombo inflammation in cardiovascular disease TTOPSTART BV participó en un H2020: H2020-MSCA-ITN-2018 The demographic change with aging populations places a heavy burden on health care systems worldwide. Despite all medical advances, age rema...
2018-08-20 - 2023-11-30 | Financiado

PIONEER: Prostate Cancer DIagnOsis and TreatmeNt Enhancement through the Power of Big Data in EuRope TTOPSTART BV participó en un H2020: H2020-JTI-IMI2-2016-10-two-stage Prostate Cancer (PCa) is the second leading cause of cancer, among men in Europe. There are currently major unmet needs in this field, such...
2018-06-14 - 2023-10-31 | Financiado

IMMUNISA: A Next Generation Immunotherapy for Human Papilloma Virus induced Cervical Cancer TTOPSTART BV participó en un H2020: H2020-SC1-2016-2017 Cervical cancer (CxCa) is caused by high risk types of the human papillomavirus (a.o. HPV16). Prophylactic HPV vaccination is not the standa...
2017-11-21 - 2022-11-30 | Financiado

ELBA: European Liquid Biopsies Academy Towards widespread clinical application of blood based diagnosti... TTOPSTART BV participó en un H2020: H2020-MSCA-ITN-2017 Liquid biopsies have been heralded as a game changer in cancer management, with blood tests offering a minimally invasive, safe, and sensiti...
2017-08-30 - 2022-09-30 | Financiado

PREDICT: A new era in personalised medicine Radiomics as decision support tool for diagnostics and theragnos... TTOPSTART BV participó en un H2020: H2020-MSCA-ITN-2017 The high degree of tumour (genomic and phenotypic) heterogeneity influences patient’s response to therapy and hampers wide deployment of per...
2017-08-29 - 2022-03-31 | Financiado

UTILE: The EU HEALTH INNOVATION MARKETPLACE the valorization platform for FP7 Health and H2020 SC1 resea... TTOPSTART BV tramitó un H2020: H2020-SC1-2016-2017 A recent evaluation of FP7 projects executed by the EC, showed that an estimated 80% of funded Health projects lacks valorisation. The UTILE...
2016-12-02 - 2019-12-31 | Financiado

PRECIOUS: Scaling up biodegradable nanomedicines for multimodal for multimodal precision cancer immunotherapy TTOPSTART BV participó en un H2020: H2020-NMP-2014-2015 PRECIOUS aims at scaling-up biodegradable nanomedicines for multimodal precision cancer immunotherapy. With 3.5 million cancer patients in E...
2016-03-17 - 2022-04-30 | Financiado

REGAIN: REgeneration of inner ear hair cells with GAmma secretase INhibitors to regain hearing in patients w... TTOPSTART BV participó en un H2020: H2020-PHC-2014-2015 Hearing loss is a chronic non-communicable disease disabling over 328 million adults, and 32 million children worldwide. Sensorineural heari...
2015-04-07 - 2019-10-31 | Financiado

InCeM: Research Training Network on Integrated Component Cycling in Epithelial Cell Motility TTOPSTART BV participó en un H2020: H2020-MSCA-ITN-2014 Cell migration (cell motility) is a fundamental biological process that is pivotal in (i) tissue formation and repair (health) and (ii) tiss...
2014-12-16 - 2018-12-31 | Financiado